Biotechnology

Genesis Capital invests in Crux Biolabs, a leading bioanalytical laboratory to the clinical trials sector

* Crux Biolabs is a decade-old Australian leader in bioanalytics, customised biomarker detection, cell assay development, clinical and pre-clinical testing with particular strength in the immuno-oncology clinical trials market * Genesis Capital is partnering with existing management to expand ...

2022-08-04 22:01 3055

CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA

* Embarking on a successful journey of exporting its home-grown product technology toNorth America, the largest market for bone substitutes * Enabling fast bone formation by applying bone morphogenetic protein (rhBMP-2) and next-generation synthetic carrier SEOUL, South Korea and LEWISVILLE, ...

2022-08-04 21:00 2134

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

* Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC * Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights inChina MELBOURNE, Australia, Aug. 3, 2022 /PRNewswire/ -- R...

2022-08-04 10:15 1368

Firmenich Appoints Maurizio Clementi ad interim President of its Taste & Beyond Division

GENEVA, Aug. 3, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, is pleased to announce the appointment ofMaurizio Clementi as ad interim President of its Taste & Beyond division, effective immediately. This move follows former PresidentEmmanuel Bu...

2022-08-03 20:57 1996

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

-   STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. -   STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...

2022-08-03 20:00 1698

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...

2022-08-03 19:38 1302

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...

2022-08-03 16:50 2075

Yidu Tech Releases FY2022 ESG Report, Using Socially Beneficial Technology to Drive the Sustainable Development of "Green Healthcare"

HONG KONG, Aug. 3, 2022 /PRNewswire/ -- The digital economy powered by innovative technologies such as artificial intelligence ("AI") and big data has become one of the most powerful drivers of economic growth since the COVID-19 outbreak, in keeping withChina's core strategy of "digitalization, ...

2022-08-03 15:09 1792

Ogawa World Berhad Won the Asia Pacific Enterprise Awards 2022 Malaysia under Inspirational Brand Category

KUALA LUMPUR, Malaysia, Aug. 3, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the 13th Asia Pacific Enterprise Awards (APEA) 2022 Malaysia, is pleased to recognize 47 exceptional business leaders and enterprises that have played a vital role in shapingMalaysia's entrepreneurial landscape...

2022-08-03 13:14 2814

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. *  ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 1834

Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...

2022-08-03 08:00 1590

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 2453

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 1904

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-08-02 21:00 1780

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 1567

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...

2022-08-02 20:50 1915

Sironax Announces Closing of $200 Million Series B Financing

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with...

2022-08-02 19:00 1919

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Na...

2022-08-02 13:00 1983

Advanced Instruments Acquires SAL Scientific, Expertise, and a Range of Cell Growth Supplements in Support of Research & Drug Discovery Workflows

NORWOOD, Mass., Aug. 2, 2022 /PRNewswire/ -- Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing, today announced the acquisition of SAL Scientific Ltd., a private company that develops and manufactures a portfolio of cell growth supplements for C...

2022-08-02 10:28 1829

GenKOre develops hypercompact adenine base editors (ABEs)

DAEJEON, South Korea, Aug. 2, 2022 /PRNewswire/ -- GenKOre, a biotech start-up in Korea, succeeded in the development of ABEs based on its own hypercompact gene-editing technology and had the relevant study published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 09:07 1998
1 ... 113114115116117118119 ... 275

Week's Top Stories